NEW YORK (GenomeWeb News) – Inform Genomics said today it has reached a deal with Tesaro to evaluate the risk of chemotherapy-induced nausea and vomiting in patients.
Using Inform Genomics' bioinformatics and genomic platforms, Tesaro will assess the risk of nausea and vomiting in patients receiving certain "moderately" emetogenic chemotherapy regimens and standard antiemetic therapy, without an NK-1 receptor antagonist, Inform said.
Financial and other terms of the deal were not disclosed.
Inform's lead platform is the OnPART, or Oncology Preference And Risk of Toxicity, system for aiding in treatment decisions for patients receiving chemotherapy for breast, colorectal, lung, or ovarian cancer. The platform is being developed to evaluate the genomic risk for six therapy-related side effects, such as diarrhea, nausea and vomiting, oral mucositis, fatigue, cognitive dysfunction, and peripheral neuropathy.
OnPART's first phase of development was recently conducted as a single center study at the West Clinic in Memphis, Tenn., and included 384 patients with breast, colorectal, lung, and ovarian cancer. The patients were treated with standard chemotherapy regiments, including dose-dense doxorubicin, cyclophosphamide, and paclitaxel for breast cancer; 5-fluoururacil and oxaliplatin-based regimens for colorectal cancer; and carboplatin plus paclitaxel-based regimens for lung and ovarian cancer.
"We believe this collaboration with Tesaro illustrates the value that our novel platforms of genomic-based personalized medicine products can provide to biopharmaceutical developers and manufacturers," Ed Rubenstein, president and CEO of Boston-based Inform Genomics, said in a statement. "Symptom science is heading in the same direction as the rest of oncology through the sophisticated use of bioinformatics, Bayesian techniques, and genomics to improve drug development and patient care."